We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


An Independent Study Documents the Benefits of Exiqon's qPCR System for microRNA Profiling of Blood Samples

Listen with
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: Less than a minute

Exiqon A/S, has announced that an independent scientific benchmark study demonstrates the superior sensitivity and linearity of the miRCURY LNA™ Universal RT microRNA PCR product line.

The benchmark study was performed by a research group at Aarhus University Hospital, Skejby, Denmark, and was published in the leading peer-reviewed scientific journal BMC Genomics.

The study highlights in particular the superior linearity and sensitivity of the miRCURY LNA™ Universal RT microRNA PCR platform within clinically important plasma and serum samples which contain low amounts of microRNA.

In the study, the research group compared the performance of the miRCURY LNA™ Universal RT microRNA PCR platform to that of two major market competitors.

The study concludes that it is beneficial to use the miRCURY platform for microRNA PCR profiling of samples with low microRNA levels, such as clinical blood samples (plasma and serum).

“microRNA profiling from minimally invasive samples, in particular serum and plasma hold great promise as a way to discover and develop important new biomarkers for diagnosis and treatment selection within a wide range of diseases” said Henrik M Pfundheller, Ph.D., SVP Sales & Marketing and added: “We are pleased to see an external study confirm the superior performance of our LNA™-enhanced microRNA PCR system within this important and promising market”.